265 related articles for article (PubMed ID: 23874405)
1. New aspects of an old drug--diclofenac targets MYC and glucose metabolism in tumor cells.
Gottfried E; Lang SA; Renner K; Bosserhoff A; Gronwald W; Rehli M; Einhell S; Gedig I; Singer K; Seilbeck A; Mackensen A; Grauer O; Hau P; Dettmer K; Andreesen R; Oefner PJ; Kreutz M
PLoS One; 2013; 8(7):e66987. PubMed ID: 23874405
[TBL] [Abstract][Full Text] [Related]
2. Tumor suppressor NDRG2 inhibits glycolysis and glutaminolysis in colorectal cancer cells by repressing c-Myc expression.
Xu X; Li J; Sun X; Guo Y; Chu D; Wei L; Li X; Yang G; Liu X; Yao L; Zhang J; Shen L
Oncotarget; 2015 Sep; 6(28):26161-76. PubMed ID: 26317652
[TBL] [Abstract][Full Text] [Related]
3. Effect of diclofenac on SLC16A3/MCT4 by the Caco-2 cell line.
Sasaki S; Futagi Y; Ideno M; Kobayashi M; Narumi K; Furugen A; Iseki K
Drug Metab Pharmacokinet; 2016 Jun; 31(3):218-23. PubMed ID: 27236641
[TBL] [Abstract][Full Text] [Related]
4. Ibuprofen and Diclofenac Restrict Migration and Proliferation of Human Glioma Cells by Distinct Molecular Mechanisms.
Leidgens V; Seliger C; Jachnik B; Welz T; Leukel P; Vollmann-Zwerenz A; Bogdahn U; Kreutz M; Grauer OM; Hau P
PLoS One; 2015; 10(10):e0140613. PubMed ID: 26485029
[TBL] [Abstract][Full Text] [Related]
5. Regulation of glucose uptake in lymphoma cell lines by c-MYC- and PI3K-dependent signaling pathways and impact of glycolytic pathways on cell viability.
Broecker-Preuss M; Becher-Boveleth N; Bockisch A; Dührsen U; Müller S
J Transl Med; 2017 Jul; 15(1):158. PubMed ID: 28724379
[TBL] [Abstract][Full Text] [Related]
6. TNFα and IL-17 cooperatively stimulate glucose metabolism and growth factor production in human colorectal cancer cells.
Straus DS
Mol Cancer; 2013 Jul; 12():78. PubMed ID: 23866118
[TBL] [Abstract][Full Text] [Related]
7. Diclofenac impairs the proliferation and glucose metabolism of triple-negative breast cancer cells by targeting the c-Myc pathway.
Yang L; Li J; Li Y; Zhou Y; Wang Z; Zhang D; Liu J; Zhang X
Exp Ther Med; 2021 Jun; 21(6):584. PubMed ID: 33850556
[TBL] [Abstract][Full Text] [Related]
8. Diclofenac inhibits lactate formation and efficiently counteracts local immune suppression in a murine glioma model.
Chirasani SR; Leukel P; Gottfried E; Hochrein J; Stadler K; Neumann B; Oefner PJ; Gronwald W; Bogdahn U; Hau P; Kreutz M; Grauer OM
Int J Cancer; 2013 Feb; 132(4):843-53. PubMed ID: 22752934
[TBL] [Abstract][Full Text] [Related]
9. Orexin A affects HepG2 human hepatocellular carcinoma cells glucose metabolism via HIF-1α-dependent and -independent mechanism.
Wan X; Liu Y; Zhao Y; Sun X; Fan D; Guo L
PLoS One; 2017; 12(9):e0184213. PubMed ID: 28886081
[TBL] [Abstract][Full Text] [Related]
10. Blocking lactate export by inhibiting the Myc target MCT1 Disables glycolysis and glutathione synthesis.
Doherty JR; Yang C; Scott KE; Cameron MD; Fallahi M; Li W; Hall MA; Amelio AL; Mishra JK; Li F; Tortosa M; Genau HM; Rounbehler RJ; Lu Y; Dang CV; Kumar KG; Butler AA; Bannister TD; Hooper AT; Unsal-Kacmaz K; Roush WR; Cleveland JL
Cancer Res; 2014 Feb; 74(3):908-20. PubMed ID: 24285728
[TBL] [Abstract][Full Text] [Related]
11. Restricting Glycolysis Preserves T Cell Effector Functions and Augments Checkpoint Therapy.
Renner K; Bruss C; Schnell A; Koehl G; Becker HM; Fante M; Menevse AN; Kauer N; Blazquez R; Hacker L; Decking SM; Bohn T; Faerber S; Evert K; Aigle L; Amslinger S; Landa M; Krijgsman O; Rozeman EA; Brummer C; Siska PJ; Singer K; Pektor S; Miederer M; Peter K; Gottfried E; Herr W; Marchiq I; Pouyssegur J; Roush WR; Ong S; Warren S; Pukrop T; Beckhove P; Lang SA; Bopp T; Blank CU; Cleveland JL; Oefner PJ; Dettmer K; Selby M; Kreutz M
Cell Rep; 2019 Oct; 29(1):135-150.e9. PubMed ID: 31577944
[TBL] [Abstract][Full Text] [Related]
12. Dihydroartemisinin and artesunate inhibit aerobic glycolysis via suppressing c-Myc signaling in non-small cell lung cancer.
Zhang Y; Wang Y; Li Y; Huang C; Xiao X; Zhong Z; Tang J; Lu H; Tang Y; Yang J
Biochem Pharmacol; 2022 Apr; 198():114941. PubMed ID: 35149053
[TBL] [Abstract][Full Text] [Related]
13. Glucose transporter 1-mediated glucose uptake is limiting for B-cell acute lymphoblastic leukemia anabolic metabolism and resistance to apoptosis.
Liu T; Kishton RJ; Macintyre AN; Gerriets VA; Xiang H; Liu X; Abel ED; Rizzieri D; Locasale JW; Rathmell JC
Cell Death Dis; 2014 Oct; 5(10):e1470. PubMed ID: 25321477
[TBL] [Abstract][Full Text] [Related]
14. Combined Modulation of Tumor Metabolism by Metformin and Diclofenac in Glioma.
Gerthofer V; Kreutz M; Renner K; Jachnik B; Dettmer K; Oefner P; Riemenschneider MJ; Proescholdt M; Vollmann-Zwerenz A; Hau P; Seliger C
Int J Mol Sci; 2018 Aug; 19(9):. PubMed ID: 30200299
[TBL] [Abstract][Full Text] [Related]
15. Metabolic targeting synergizes with MAPK inhibition and delays drug resistance in melanoma.
Brummer C; Faerber S; Bruss C; Blank C; Lacroix R; Haferkamp S; Herr W; Kreutz M; Renner K
Cancer Lett; 2019 Feb; 442():453-463. PubMed ID: 30481565
[TBL] [Abstract][Full Text] [Related]
16. MEK1/2 inhibition decreases lactate in BRAF-driven human cancer cells.
Falck Miniotis M; Arunan V; Eykyn TR; Marais R; Workman P; Leach MO; Beloueche-Babari M
Cancer Res; 2013 Jul; 73(13):4039-49. PubMed ID: 23639941
[TBL] [Abstract][Full Text] [Related]
17. Overexpression of
Hippner-Kunicka M; Laszkiewicz A; Skrzymowska J; Biecek P; Donizy P; Miazek A
Anticancer Res; 2023 Jun; 43(6):2527-2538. PubMed ID: 37247894
[TBL] [Abstract][Full Text] [Related]
18. Metabolic coupling and the Reverse Warburg Effect in cancer: Implications for novel biomarker and anticancer agent development.
Wilde L; Roche M; Domingo-Vidal M; Tanson K; Philp N; Curry J; Martinez-Outschoorn U
Semin Oncol; 2017 Jun; 44(3):198-203. PubMed ID: 29248131
[TBL] [Abstract][Full Text] [Related]
19. Targeting the monocarboxylate transporter MCT2 and lactate dehydrogenase A LDHA in cancer cells with FX-11 and AR-C155858 inhibitors.
Alobaidi B; Hashimi SM; Alqosaibi AI; AlQurashi N; Alhazmi S
Eur Rev Med Pharmacol Sci; 2023 Jul; 27(14):6605-6617. PubMed ID: 37522672
[TBL] [Abstract][Full Text] [Related]
20. Metabolic targeting of oncogene MYC by selective activation of the proton-coupled monocarboxylate family of transporters.
Gan L; Xiu R; Ren P; Yue M; Su H; Guo G; Xiao D; Yu J; Jiang H; Liu H; Hu G; Qing G
Oncogene; 2016 Jun; 35(23):3037-48. PubMed ID: 26434591
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
